Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 38 entries
Sorted by: Best Match Show Resources per page
Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction.

Journal of medical biochemistry

Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, Marinkovic J, Mitrovic P, Mrdovic I, Stankovic S, Kružliak P, Beleslin B, Uscumlic A, Kostic J.
PMID: 28356876
J Med Biochem. 2016 Apr;35(2):158-165. doi: 10.1515/jomb-2016-0003. Epub 2016 May 09.

BACKGROUND: Since serial analyses of NT-proBNP in patients with acute coronary syndromes have shown that levels measured during a chronic, later phase are a better predictor of prognosis and indicator of left ventricular function than the levels measured during...

Cite
Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, et al. Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. J Med Biochem. 2016;35(2):158-165doi: 10.1515/jomb-2016-0003.
Radosavljevic-Radovanovic, M., Radovanovic, N., Vasiljevic, Z., Marinkovic, J., Mitrovic, P., Mrdovic, I., Stankovic, S., Kružliak, P., Beleslin, B., Uscumlic, A., & Kostic, J. (2016). Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. Journal of medical biochemistry, 35(2), 158-165. https://doi.org/10.1515/jomb-2016-0003
Radosavljevic-Radovanovic, Mina, et al. "Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction." Journal of medical biochemistry vol. 35,2 (2016): 158-165. doi: https://doi.org/10.1515/jomb-2016-0003
Radosavljevic-Radovanovic M, Radovanovic N, Vasiljevic Z, Marinkovic J, Mitrovic P, Mrdovic I, Stankovic S, Kružliak P, Beleslin B, Uscumlic A, Kostic J. Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction. J Med Biochem. 2016 Apr;35(2):158-165. doi: 10.1515/jomb-2016-0003. Epub 2016 May 09. PMID: 28356876; PMCID: PMC5346793.
Copy Download .nbib Format: NLM
Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing.

American journal of nuclear medicine and molecular imaging

Gaspar L, Reich M, Kassai Z, Macasek F, Rodrigo L, Kruzliak P, Kovac P.
PMID: 27508102
Am J Nucl Med Mol Imaging. 2016 Jul 06;6(3):154-65. eCollection 2016.

Nine years of experience with 2286 commercial synthesis allowed us to deliver comprehensive information on the quality of (18)F-FDG production. Semi-automated FDG production line using Cyclone 18/9 machine (IBA Belgium), TRACERLab MXFDG synthesiser (GE Health, USA) using alkalic hydrolysis,...

Cite
Gaspar L, Reich M, Kassai Z, et al. Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing. Am J Nucl Med Mol Imaging. 2016;6(3):154-65
Gaspar, L., Reich, M., Kassai, Z., Macasek, F., Rodrigo, L., Kruzliak, P., & Kovac, P. (2016). Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing. American journal of nuclear medicine and molecular imaging, 6(3), 154-65.
Gaspar, Ludovit, et al. "Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing." American journal of nuclear medicine and molecular imaging vol. 6,3 (2016): 154-65.
Gaspar L, Reich M, Kassai Z, Macasek F, Rodrigo L, Kruzliak P, Kovac P. Long-term quality assurance of [(18)F]-fluorodeoxyglucose (FDG) manufacturing. Am J Nucl Med Mol Imaging. 2016 Jul 06;6(3):154-65. eCollection 2016. PMID: 27508102; PMCID: PMC4965520.
Copy Download .nbib Format: NLM
fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli.

Frontiers in psychology

Alink A, Krugliak A, Walther A, Kriegeskorte N.
PMID: 23964251
Front Psychol. 2013 Aug 12;4:493. doi: 10.3389/fpsyg.2013.00493. eCollection 2013.

The orientation of a large grating can be decoded from V1 functional magnetic resonance imaging (fMRI) data, even at low resolution (3-mm isotropic voxels). This finding has suggested that columnar-level neuronal information might be accessible to fMRI at 3T....

Cite
Alink A, Krugliak A, Walther A, et al. fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Front Psychol. 2013;4:493doi: 10.3389/fpsyg.2013.00493.
Alink, A., Krugliak, A., Walther, A., & Kriegeskorte, N. (2013). fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Frontiers in psychology, 4493. https://doi.org/10.3389/fpsyg.2013.00493
Alink, Arjen, et al. "fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli." Frontiers in psychology vol. 4 (2013): 493. doi: https://doi.org/10.3389/fpsyg.2013.00493
Alink A, Krugliak A, Walther A, Kriegeskorte N. fMRI orientation decoding in V1 does not require global maps or globally coherent orientation stimuli. Front Psychol. 2013 Aug 12;4:493. doi: 10.3389/fpsyg.2013.00493. eCollection 2013. PMID: 23964251; PMCID: PMC3740242.
Copy Download .nbib Format: NLM
Modifications of anxiety-like behavior in prenatally stressed male offspring with imbalance of androgens.

American journal of translational research

Fedotova J, Akulova V, Pivina S, Dragasek J, Caprnda M, Kruzliak P.
PMID: 28386370
Am J Transl Res. 2017 Mar 15;9(3):1448-1459. eCollection 2017.

Gonadal hormones have been well-known to affect brain regions known to be involved in the modulation of mood and affective-related behavior. Prenatal stress might alter hypothalamic-pituitary-gonadal axis, it could be a target for development of affective-related disorders in male...

Cite
Fedotova J, Akulova V, Pivina S, et al. Modifications of anxiety-like behavior in prenatally stressed male offspring with imbalance of androgens. Am J Transl Res. 2017;9(3):1448-1459
Fedotova, J., Akulova, V., Pivina, S., Dragasek, J., Caprnda, M., & Kruzliak, P. (2017). Modifications of anxiety-like behavior in prenatally stressed male offspring with imbalance of androgens. American journal of translational research, 9(3), 1448-1459.
Fedotova, Julia, et al. "Modifications of anxiety-like behavior in prenatally stressed male offspring with imbalance of androgens." American journal of translational research vol. 9,3 (2017): 1448-1459.
Fedotova J, Akulova V, Pivina S, Dragasek J, Caprnda M, Kruzliak P. Modifications of anxiety-like behavior in prenatally stressed male offspring with imbalance of androgens. Am J Transl Res. 2017 Mar 15;9(3):1448-1459. eCollection 2017. PMID: 28386370; PMCID: PMC5376035.
Copy Download .nbib Format: NLM
Should we routinely assess coronary artery Doppler in daily echocardiography practice?.

Acta cardiologica

Zagatina A, Zhuravskaya N, Caprnda M, Shiwani HA, Gazdikova K, Rodrigo L, Kruzliak P, Shmatov D.
PMID: 34538214
Acta Cardiol. 2021 Sep 19;1-7. doi: 10.1080/00015385.2021.1973771. Epub 2021 Sep 19.

A lot of people with coronary artery disease do not have specific symptoms, and myocardial infarction or death are the first manifestation of the disease. New accurate, non-invasive and safe screening methods are required that can assess the prognosis...

Cite
Zagatina A, Zhuravskaya N, Caprnda M, et al. Should we routinely assess coronary artery Doppler in daily echocardiography practice?. Acta Cardiol. 2021;1-7doi: 10.1080/00015385.2021.1973771.
Zagatina, A., Zhuravskaya, N., Caprnda, M., Shiwani, H. A., Gazdikova, K., Rodrigo, L., Kruzliak, P., & Shmatov, D. (2021). Should we routinely assess coronary artery Doppler in daily echocardiography practice?. Acta cardiologica, 1-7. https://doi.org/10.1080/00015385.2021.1973771
Zagatina, Angela, et al. "Should we routinely assess coronary artery Doppler in daily echocardiography practice?." Acta cardiologica vol. (2021): 1-7. doi: https://doi.org/10.1080/00015385.2021.1973771
Zagatina A, Zhuravskaya N, Caprnda M, Shiwani HA, Gazdikova K, Rodrigo L, Kruzliak P, Shmatov D. Should we routinely assess coronary artery Doppler in daily echocardiography practice?. Acta Cardiol. 2021 Sep 19;1-7. doi: 10.1080/00015385.2021.1973771. Epub 2021 Sep 19. PMID: 34538214.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Probiotics in prevention and treatment of obesity: a critical view.

Nutrition & metabolism

Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, Rodrigo L, Kruzliak P.
PMID: 26900391
Nutr Metab (Lond). 2016 Feb 20;13:14. doi: 10.1186/s12986-016-0067-0. eCollection 2016.

The worldwide prevalence of obesity more than doubled between 1980 and 2014. The obesity pandemic is tightly linked to an increase in energy availability, sedentariness and greater control of ambient temperature that have paralleled the socioeconomic development of the...

Cite
Kobyliak N, Conte C, Cammarota G, et al. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond). 2016;13:14doi: 10.1186/s12986-016-0067-0.
Kobyliak, N., Conte, C., Cammarota, G., Haley, A. P., Styriak, I., Gaspar, L., Fusek, J., Rodrigo, L., & Kruzliak, P. (2016). Probiotics in prevention and treatment of obesity: a critical view. Nutrition & metabolism, 1314. https://doi.org/10.1186/s12986-016-0067-0
Kobyliak, Nazarii, et al. "Probiotics in prevention and treatment of obesity: a critical view." Nutrition & metabolism vol. 13 (2016): 14. doi: https://doi.org/10.1186/s12986-016-0067-0
Kobyliak N, Conte C, Cammarota G, Haley AP, Styriak I, Gaspar L, Fusek J, Rodrigo L, Kruzliak P. Probiotics in prevention and treatment of obesity: a critical view. Nutr Metab (Lond). 2016 Feb 20;13:14. doi: 10.1186/s12986-016-0067-0. eCollection 2016. PMID: 26900391; PMCID: PMC4761174.
Copy Download .nbib Format: NLM
Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications.

Stem cells international

Russo E, Caprnda M, Kruzliak P, Conaldi PG, Borlongan CV, La Rocca G.
PMID: 35035489
Stem Cells Int. 2022 Jan 06;2022:2454168. doi: 10.1155/2022/2454168. eCollection 2022.

Chondropathies are increasing worldwide, but effective treatments are currently lacking. Mesenchymal stromal cell (MSCs) transplantation represents a promising approach to counteract the degenerative and inflammatory environment characterizing those pathologies, such as osteoarthritis (OA) and rheumatoid arthritis (RA). Umbilical cord-...

Cite
Russo E, Caprnda M, Kruzliak P, et al. Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications. Stem Cells Int. 2022;2022:2454168doi: 10.1155/2022/2454168.
Russo, E., Caprnda, M., Kruzliak, P., Conaldi, P. G., Borlongan, C. V., & La Rocca, G. (2022). Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications. Stem cells international, 20222454168. https://doi.org/10.1155/2022/2454168
Russo, E, et al. "Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications." Stem cells international vol. 2022 (2022): 2454168. doi: https://doi.org/10.1155/2022/2454168
Russo E, Caprnda M, Kruzliak P, Conaldi PG, Borlongan CV, La Rocca G. Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications. Stem Cells Int. 2022 Jan 06;2022:2454168. doi: 10.1155/2022/2454168. eCollection 2022. PMID: 35035489; PMCID: PMC8758292.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα.

Gastroenterology

Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I.
PMID: 34717923
Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28.

BACKGROUND & AIM: Patients with inflammatory bowel diseases (IBD), specifically those treated with anti-tumor necrosis factor (TNF)α biologics, are at high risk for vaccine-preventable infections. Their ability to mount adequate vaccine responses is unclear. The aim of the study...

Cite
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, et al. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021;doi: 10.1053/j.gastro.2021.10.029.
Edelman-Klapper, H., Zittan, E., Bar-Gil Shitrit, A., Rabinowitz, K. M., Goren, I., Avni-Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., Yanai, H., Snir, Y., Pauker, M. H., Friedenberg, A., Levy-Barda, A., Segal, A., Broitman, Y., Maoz, E., Ovadia, B., Golan, M. A., Shachar, E., Ben-Horin, S., Perets, T. T., Ben Zvi, H., Eliakim, R., Barkan, R., Goren, S., Navon, M., Krugliak, N., Werbner, M., Alter, J., Dessau, M., Gal-Tanamy, M., Freund, N. T., Cohen, D., Dotan, I. (2021). Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology, . https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper, Hadar, et al. "Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα." Gastroenterology vol. (2021). doi: https://doi.org/10.1053/j.gastro.2021.10.029
Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology. 2021 Oct 28; doi: 10.1053/j.gastro.2021.10.029. Epub 2021 Oct 28. PMID: 34717923; PMCID: PMC8552587.
Copy Download .nbib Format: NLM
Dynamics of coronary artery velocity flow during exercise echocardiography.

Acta cardiologica

Zagatina A, Zhuravskaya N, Caprnda M, Rodrigo L, Kruzliak P.
PMID: 34275429
Acta Cardiol. 2021 Jul 19;1-7. doi: 10.1080/00015385.2021.1952001. Epub 2021 Jul 19.

PURPOSE: The aim of our study was to acquire non-invasive data from coronary flow velocity profiles during exercise in groups of healthy subjects and of patients with arterial hypertension.MATERIAL AND METHODS: We enrolled 83 patients into two groups: (1)...

Cite
Zagatina A, Zhuravskaya N, Caprnda M, et al. Dynamics of coronary artery velocity flow during exercise echocardiography. Acta Cardiol. 2021;1-7doi: 10.1080/00015385.2021.1952001.
Zagatina, A., Zhuravskaya, N., Caprnda, M., Rodrigo, L., & Kruzliak, P. (2021). Dynamics of coronary artery velocity flow during exercise echocardiography. Acta cardiologica, 1-7. https://doi.org/10.1080/00015385.2021.1952001
Zagatina, Angela, et al. "Dynamics of coronary artery velocity flow during exercise echocardiography." Acta cardiologica vol. (2021): 1-7. doi: https://doi.org/10.1080/00015385.2021.1952001
Zagatina A, Zhuravskaya N, Caprnda M, Rodrigo L, Kruzliak P. Dynamics of coronary artery velocity flow during exercise echocardiography. Acta Cardiol. 2021 Jul 19;1-7. doi: 10.1080/00015385.2021.1952001. Epub 2021 Jul 19. PMID: 34275429.
Copy Download .nbib Format: NLM
Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library.

Pharmaceuticals (Basel, Switzerland)

Tomar PPS, Krugliak M, Arkin IT.
PMID: 34201587
Pharmaceuticals (Basel). 2021 Jun 23;14(7). doi: 10.3390/ph14070604.

SARS-CoV-2, the etiological agent of the COVID-19 pandemic, is a member of the Coronaviridae family. It is an enveloped virus with ion channels in its membrane, the most characterized of which is the E protein. Therefore, in an attempt...

Cite
Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel). 2021;14(7)doi: 10.3390/ph14070604.
Tomar, P. P. S., Krugliak, M., & Arkin, I. T. (2021). Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel, Switzerland), 14(7), . https://doi.org/10.3390/ph14070604
Tomar, Prabhat Pratap Singh, et al. "Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library." Pharmaceuticals (Basel, Switzerland) vol. 14,7 (2021). doi: https://doi.org/10.3390/ph14070604
Tomar PPS, Krugliak M, Arkin IT. Identification of SARS-CoV-2 E Channel Blockers from a Repurposed Drug Library. Pharmaceuticals (Basel). 2021 Jun 23;14(7). doi: 10.3390/ph14070604. PMID: 34201587; PMCID: PMC8308726.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 38 entries